Technical Analysis for ALXO - ALX Oncology Holdings Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | Up | Down |
| Historical ALXO trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Narrow Range Bar | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| NR7-2 | Range Contraction | 0.00% | |
| NR7 | Range Contraction | 0.39% | |
| Fell Below 20 DMA | Bearish | 1.41% | |
| Multiple of Ten Bullish | Other | 1.41% | |
| Lower Bollinger Band Touch | Weakness | 1.41% | |
| 20 DMA Support | Bullish | -3.33% | |
| NR7 | Range Contraction | -3.33% | |
| Crossed Above 20 DMA | Bullish | -3.07% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Trending on StockTwits | about 8 hours ago | |
| 60 Minute Opening Range Breakdown | 1 day ago | |
| Fell Below Previous Day's Low | 1 day ago | |
| Down 1% | 1 day ago | |
| 10 DMA Resistance | 1 day ago |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: ???
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic used for the treatment of myelodysplastic syndromes and acute myeloid leukemia, as well as a range of solid tumor indications, including head and neck squamous cell and human epidermal growth factor receptor 2 positive gastric/gastroesophageal junction carcinoma. The company was founded in 2015 and is based in Burlingame, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Epidermal Growth Factor Receptor Myelodysplastic Syndrome Syndromes Solid Tumor Myelodysplastic Syndromes CD47 Treatment Of Myelodysplastic Syndrome
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Oncology Cancer Immunotherapy Acute Myeloid Leukemia Carcinoma Epidermal Growth Factor Receptor Myelodysplastic Syndrome Syndromes Solid Tumor Myelodysplastic Syndromes CD47 Treatment Of Myelodysplastic Syndrome
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 117.45 |
| 52 Week Low | 28.01 |
| Average Volume | 199,273 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 75.19 |
| 20-Day Moving Average | 85.76 |
| 10-Day Moving Average | 84.47 |
| Average True Range | 7.34 |
| ADX | 43.96 |
| +DI | 25.96 |
| -DI | 17.21 |
| Chandelier Exit (Long, 3 ATRs ) | 75.13 |
| Chandelier Exit (Short, 3 ATRs ) | 99.21 |
| Upper Bollinger Band | 91.67 |
| Lower Bollinger Band | 79.86 |
| Percent B (%b) | 0.29 |
| BandWidth | 13.77 |
| MACD Line | 2.07 |
| MACD Signal Line | 3.36 |
| MACD Histogram | -1.2925 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 88.73 | ||||
| Resistance 3 (R3) | 88.68 | 86.83 | 87.83 | ||
| Resistance 2 (R2) | 86.83 | 85.45 | 86.86 | 87.53 | |
| Resistance 1 (R1) | 85.08 | 84.61 | 85.96 | 85.13 | 87.23 |
| Pivot Point | 83.23 | 83.23 | 83.67 | 83.26 | 83.23 |
| Support 1 (S1) | 81.48 | 81.85 | 82.36 | 81.53 | 79.43 |
| Support 2 (S2) | 79.63 | 81.01 | 79.66 | 79.13 | |
| Support 3 (S3) | 77.88 | 79.63 | 78.83 | ||
| Support 4 (S4) | 77.93 |
